🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/04/2009 | 27,30 | 29,39 | 27,30 | 29,02 | +7,32% | 7,66% | 3.711.300 |
| 24/04/2009 | 26,92 | 27,30 | 26,38 | 27,04 | +1,58% | 3,42% | 2.375.400 |
| 23/04/2009 | 26,00 | 26,73 | 25,94 | 26,62 | -0,78% | 3,04% | 2.332.000 |
| 22/04/2009 | 26,61 | 27,65 | 26,51 | 26,83 | -0,70% | 4,28% | 1.996.800 |
| 21/04/2009 | 27,65 | 27,98 | 26,41 | 27,02 | -2,14% | 5,68% | 2.048.000 |
| 20/04/2009 | 27,43 | 28,22 | 27,43 | 27,61 | -1,50% | 2,88% | 2.309.000 |
| 17/04/2009 | 27,93 | 28,43 | 27,27 | 28,03 | +0,72% | 4,15% | 2.336.300 |
| 16/04/2009 | 27,37 | 28,37 | 27,11 | 27,83 | +2,85% | 4,60% | 2.329.000 |
| 15/04/2009 | 27,19 | 27,43 | 26,56 | 27,06 | -1,42% | 3,20% | 2.082.000 |
| 14/04/2009 | 27,31 | 28,92 | 27,02 | 27,45 | +0,51% | 6,96% | 3.738.800 |
| 13/04/2009 | 26,50 | 27,36 | 26,42 | 27,31 | +1,64% | 3,55% | 1.580.000 |
| 09/04/2009 | 26,90 | 27,17 | 26,43 | 26,87 | +1,17% | 2,75% | 1.718.100 |
| 08/04/2009 | 26,69 | 26,75 | 26,14 | 26,56 | +1,26% | 2,29% | 1.758.100 |
| 07/04/2009 | 26,77 | 26,81 | 26,03 | 26,23 | -3,03% | 2,91% | 1.428.200 |
| 06/04/2009 | 26,92 | 27,24 | 26,42 | 27,05 | -1,02% | 3,05% | 2.014.100 |
| 03/04/2009 | 28,75 | 28,75 | 26,91 | 27,33 | -3,56% | 6,40% | 1.968.500 |
| 02/04/2009 | 28,48 | 28,83 | 28,17 | 28,34 | -0,49% | 2,32% | 1.905.100 |
| 01/04/2009 | 28,46 | 28,52 | 27,81 | 28,48 | -0,87% | 2,49% | 1.787.600 |
| 31/03/2009 | 28,89 | 29,33 | 28,36 | 28,73 | +0,21% | 3,36% | 1.917.800 |
| 30/03/2009 | 29,02 | 29,41 | 28,22 | 28,67 | -2,58% | 4,10% | 2.371.700 |
| 27/03/2009 | 29,65 | 30,00 | 29,39 | 29,43 | -2,49% | 2,06% | 1.558.200 |
| 26/03/2009 | 29,68 | 30,19 | 29,11 | 30,18 | +3,46% | 3,64% | 2.808.400 |
| 25/03/2009 | 29,54 | 30,02 | 28,37 | 29,17 | -0,03% | 5,59% | 1.509.900 |
| 24/03/2009 | 29,56 | 30,22 | 29,18 | 29,18 | -3,12% | 3,52% | 1.280.400 |
| 23/03/2009 | 29,50 | 30,29 | 29,04 | 30,12 | +4,62% | 4,24% | 1.765.700 |
| 20/03/2009 | 29,32 | 30,14 | 28,69 | 28,79 | -1,84% | 4,95% | 3.884.400 |
| 19/03/2009 | 29,75 | 30,00 | 28,75 | 29,33 | -0,58% | 4,20% | 2.208.300 |
| 18/03/2009 | 28,90 | 29,80 | 28,35 | 29,50 | +2,57% | 5,02% | 4.144.800 |
| 17/03/2009 | 27,64 | 28,90 | 27,42 | 28,76 | +4,73% | 5,35% | 2.790.800 |
| 16/03/2009 | 28,50 | 29,65 | 27,34 | 27,46 | -5,64% | 8,11% | 3.329.000 |